Background: An important goal of intermittent strategies of delivering systemic treatment as first-line treatment of metastatic colorectal cancer (mCRC) is to maintain efficacy while improving patients' quality of life (QoL). Given the varying impact on efficacy demonstrated in individual randomized, controlled trials (RCTs), a systematic review and meta-analysis of RCTs of these intermittent strategies was carried out.
Since the late 1990s, new effective cytotoxic and biologic agents have emerged for the treatment of unresectable metastatic colorectal cancer (mCRC), and randomized trials have demonstrated the benefits of adding these agents to the traditional standard fluoropyrimidine therapy. The median survival of patients treated with these regimens is now more than 20 months in randomized trials [2] . As patients live longer, it also means a longer exposure to the toxicities of systemic therapies. A number of randomized trials have now studied strategies to ameliorate the toxicities that patients experience. These intermittent chemotherapy strategies generally involve an induction period with chemotherapy (with or without a biologic) followed by a period during which one or all of the chemotherapy drugs are discontinued, followed by reintroduction of the induction chemotherapy at some point. While one of the important goals of these 'stop-and-go' strategies is to reduce side-effects and improve patients' quality of life (QoL), it is also important to understand the impact of these strategies on efficacy. 
study selection criteria
Articles were included if they were published English-language abstracts or fully published reports of phase II or III randomized, controlled trials (RCTs) comparing continuous chemotherapy to an intermittent strategy of chemotherapy, with or without maintenance therapy, in adult patients with mCRC and included at least one of the outcomes of interest. Syntheses of RCTs in the form of systematic reviews or meta-analyses were also eligible. If more than one study evaluated the same dataset, only the most recent paper was selected for inclusion. Evidence was selected and reviewed by one clinician (SB) and one methodologist (RC) from the Ontario Program in Evidence-Based Care Gastrointestinal Disease Site Group working group.
synthesizing the evidence
Data were pooled using the Review Manager software (RevMan 5.1) provided by the Cochrane Collaboration [3] . Since hazard ratios (HRs), rather than the number of events at a certain time point, are the preferred statistic for pooling time-to-event outcomes [4] , those were extracted directly from the most recently reported trial results. The variances of the HR estimates were calculated from the reported confidence intervals (CIs) using the methods described by Parmar et al. [4] . A random effects model was used for all pooling.
Statistical heterogeneity was calculated using the χ 2 test for heterogeneity and the I 2 percentage. A probability level for the χ 2 statistic ≤10% (P ≤ 0.10) and/or an I 2 > 50% were considered indicative of statistical heterogeneity. Results are expressed as HRs with 95% CIs. An HR <1.0 indicates that patients receiving intermittent chemotherapy had a lower probability of experiencing an event (death).
Meta-analyses were only conducted on the overall survival (OS) outcome. Given the number of induction and maintenance strategies used in the included trials, after a meta-analysis was conducted on all trials, sensitivity analyses were conducted to determine the robustness of findings across the spectrum of strategies. Some of these sensitivity analyses were suggested during the formal review process (https://www.cancercare.on.ca/ common/pages/UserFile.aspx?fileId=294221). Subgroup analyses were conducted to explore robustness of the findings across induction and maintenance strategies.
results

literature search results
The Medline search yielded 560 hits, of which 25 were potentially relevant and were fully reviewed. Six were retained. The EMBASE search yielded 1618 hits, of which 9 were potentially relevant and were fully reviewed. Two of these were retained. Twelve abstracts from ASCO were retrieved and three were retained. Ten abstracts from ESMO/ECC were retrieved and one was retained (supplementary Figure S2 , available at Annals of Oncology online). Survival and QoL data for one trial were contained in two separate abstracts. Therefore, 11 trials were described in 12 publications. outcomes study/trial design. All 11 trials [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] involved adult patients with inoperable locoregional or mCRC comparing continuous first-line chemotherapy until disease progression (PD) to a planned intermittent chemotherapy strategy (Table 1) . Patients had no prior treatment of metastatic disease in all trials. Eight of the trials were superiority trials [5-9, 14, 15] and three were noninferiority trials [10, 11, 13] . The intermittent chemotherapy arms in each of the trials varied in some key features including how the intermittent strategy was administered; duration of induction in the intermittent arm, when reintroduction of the induction chemotherapy in the intermittent arm occurred, and the definition of disease progression (supplementary Table S1 , available at Annals of Oncology online). All trials continued the intermittent component of the strategy until disease progression except the Labianca trial [11] , which used an '8 week on, 8 week off' treatment schedule after starting.
Information regarding trial quality can be found online in supplementary Table S2 , available at Annals of Oncology online.
response and survival. Seven of the trials report overall response rate (ORR) for the ITT population [5, 6, 9, 10, [13] [14] [15] . In all seven of these trials, ORR was similar for the intermittent and continuous chemotherapy arms, although only three [6, 10, 15] report that the difference found is nonsignificant ( Table 2) . Progression-free survival (PFS) for the ITT population is reported in seven trials [5, 6, 9, [12] [13] [14] [15] but is only significantly different in three of the trials [9, 12, 15] . Specifically, in the OPTIMOX2 [9] and CAIRO3 [12] trials, PFS was significantly longer in the continuous chemotherapy arm (P = 0.0017 and P < 0.0001, respectively), whereas in the Yalcin et al. [15] trial, PFS was significantly longer in the intermittent arm (P = 0.002).
Median OS data were available for 10 of the 11 trials [5, 6, [8] [9] [10] [11] [12] [13] [14] [15] , and HRs were available for 8 trials [5, 6, [9] [10] [11] [12] [13] [14] . There was no significant difference between intermittent and continuous chemotherapy in the ITT population in any of these trials. Meta-analysis of all the trials includes more than 3000 patients and demonstrates no statistically significant difference between chemotherapy strategies (HR, 1.03; 95% CI 0.965-1.10, P = 0.38) (Figure 1 ).
Several additional subgroup analyses were conducted as follows. Forest plots of these meta-analyses are available in the supplementary material, available at Annals of Oncology online.
all trials with maintenance therapy
A meta-analysis of all trials with maintenance therapy (Table 3) (single-agent and combination trials) (supplementary Figure S3 , available at Annals of Oncology online) demonstrates no significant difference between continuous and intermittent chemotherapy [11] Overall survival Noninferiority Intermittent (FOLFIRI every 2 weeks and 2 months on, 2 months off until PD) Continuous (FOLFIRI every 2 weeks until PD)
167 (147) 170 ( with respect to OS (HR, 1.00; 95% CI 0.88-1.14, P = 0.99) and no heterogeneity.
All trials with no maintenance therapy
Meta-analysis of all trials with no maintenance therapy (Table 3) (single-agent and combination chemotherapy induction trials) (supplementary Figure S4 , available at Annals of Oncology online) demonstrates no statistically significant difference in OS (HR, 1.03; 95% CI 0.94-1.14, P = 0.50) and low heterogeneity [18] .
All combination trials
Meta-analysis of all combination chemotherapy trials (Table 3) (supplementary Figure S5 , available at Annals of Oncology online) demonstrates no significant difference between intermittent and continuous chemotherapy strategies (HR, 1.05; 95% CI 0.98-1.13, P = 0.19).
combination trials by maintenance strategy
These subgroup analyses were carried out to examine the impact of the different induction and maintenance strategies on OS (Table 3) . Only those subgroups with at least two studies for which HRs are available are shown (supplementary Figure S6 , available at Annals of Oncology online). Only one of these subgroup analyses demonstrated a significant difference in OS between continuous and intermittent chemotherapy strategies. This analysis of the three trials [9, 10, 12] (n = 2403) with combination treatment induction and no maintenance until progression (i.e. excluding Labianca) revealed a statistically significant benefit for continuous treatment (HR = 1.10, 95% CI 1.00-1.20, P = 0.05). None of these meta-analyses demonstrates any heterogeneity. Table 3 summarizes the results of all the meta-analysis conducted.
toxicity. With respect to grade 3-4 hematologic toxicity, there were similar rates of anemia with both chemotherapy strategies in all the trials that reported this outcome. There were more cases of neutropenia with continuous chemotherapy in OPTIMOX1 [6] , OPTIMOX2 [9] , and in Yalcin et al. [15] , although it was only significant in OPTIMOX1 (P = 0.002) (supplementary Table S3 , available at Annals of Oncology online). Thrombocytopenia results were mixed. Of the five trials that reported this outcome, the incidence was similar for both chemotherapy strategies in three of the trials [5, 11, 14] , nonsignificantly increased in the continuous chemotherapy arm of OPTIMOX2 [9] and significantly increased for the intermittent chemotherapy arm in OPTIMOX1 [6] .
Incidence of grade 3-4 nonhematologic toxicities tended to be similar for both chemotherapy strategies (supplementary Table S3 , available at Annals of Oncology online). However, the intermittent strategy resulted in significantly more cases of the following outcomes in the trials noted: nausea/vomiting [6] , mucositis [6] , and hand-foot syndrome/rash [6, 14] . The continuous chemotherapy strategy resulted in significantly more cases of the following outcomes in the trials noted: fatigue [13] , neurologic toxicity [13] , and hand-foot syndrome [13] . quality of life. Only three of the trials reported QoL data [5, 10, 19] . Maughan et al. [5] More than 70% of patients in each arm started completing the QoL instruments in each arm but by 30 weeks, <30% of those that started were still completing QoL forms. They report that the patients in the intermittent and continuous chemotherapy arms of the trial were similar with respect to physical functioning, overall health, general symptoms and psychological distress [5] . In addition, most of the patients in both groups reported that they felt that their treatment was worthwhile. COIN [10] administered the EORTC QLQ C30 as well as five other questions to patients at baseline, six weeks, 12 weeks and every 12 weeks thereafter. The QoL questionnaires were completed by less than 67% of patients. There were no differences in the baseline characteristics between those who completed the QoL questionnaires and all patients randomized but the authors noted that they could not eliminate the possibility of differences existing. At baseline there were no significant differences in QoL measures between patients in the two arms of the trial. At 12 weeks, there was only a significant detriment with respect to problems in eating or drinking for those in the intermittent chemotherapy arm (OR, 1.23; 95% CI 1.00-1.50, P = 0.045). At 24 weeks, there were significant benefits for the intermittent chemotherapy arm for role functioning (OR, 0.82; 95% CI 0.70-0.96, P = 0.015) and social functioning (OR, 0.82; 95% CI 0.70-0.96, P = 0.016). At this time point, there were also significant benefits for the intermittent chemotherapy arm for several symptom scales including fatigue, nausea and vomiting, appetite loss, constipation, diarrhea, dry or sore mouth, eating or drinking problems, problems handling small objects, and treatment interfering with activities of daily living (all P < 0.04). At 12 weeks, there was a significant detriment for intermittent chemotherapy for pain (OR, 1.38; 95% CI 1.16-1.64, P = 0.00029).
In CAIRO3 [19] QoL data were available for 491 of the 558 patients (88%), but there is no information on the QoL instruments used. There were statistically significant improvements Figure 1 Meta-analysis for overall survival: all trials. 
discussion
Our systematic review and meta-analysis synthesized the evidence from the available randomized trials comparing continuous chemotherapy to a variety of intermittent strategies of delivering therapies for the first-line treatment of unresectable mCRC. The key findings of our analysis are that, compared with continuous chemotherapy, the intermittent strategies did not have a significant impact on OS and either maintained or improved QoL. Moreover, our findings regarding OS were robust across the range of induction and maintenance strategies used in the randomized trials. Although the results of our analysis cannot be interpreted as showing equivalence of the two strategies, the analysis does demonstrate that there is no statistical evidence to show a clinically important difference between the two strategies. In contrast to our findings regarding OS, another recent systematic review and meta-analysis by Pereira et al. [20] comparing intermittent and continuous chemotherapy strategies concludes that continuous chemotherapy has a significant, albeit modest, improvement in survival (HR, 0.89; 95% CI 0.82-0.98, P = 0.01) over intermittent chemotherapy. However, there are two main concerns with the systematic review. It only included five of the available randomized trials included in our analysis and the COIN-B trial [21] . COIN-B does not have a true continuous chemotherapy arm. After a 12-week induction with combination chemotherapy and cetuximab, patients were randomized to either single-agent cetuximab as maintenance vs. a complete break from therapy. Therefore, it was not included in the present systematic review. Second, the forest plot of the Pereira et al. [20] meta-analysis shows the Maughan et al. trial [5] to have an OS HR of 0.87 in favor of continuous chemotherapy when, in fact, the OS HR in this trial is 0.87 in favor of intermittent chemotherapy. Given that the Maughan et al. [5] trial accounts for 17.1% of the result and the CI for the HR is so close to 1.00, it is likely that the conclusion of the Pereira et al. [20] systematic review will not be maintained when this error is corrected.
The results of our analysis for OS were generally robust across subgroup analyses of different induction and maintenance regimens. One subgroup analysis (supplementary Figure S6 , available at Annals of Oncology online-part 4.7.2) may be the most relevant to current practice in that it includes three trials (9, 10, 12) that include a combination chemotherapy induction (unlike Maughan et al.) and have chemotherapy-free intervals that continue until progression of disease in the intermittent arm (unlike Labianca et al.) . The HR for OS in the sensitivity analysis was 1.10 (95% CI 1.00-1.20, P = 0.049), a statistically significant detriment in OS. However, there are two caveats. First, although statistically significant, the OS HR is of questionable clinical significance. Second, these conclusions would only apply to the results of one subgroup analysis, albeit the most clinically relevant one.
A recent analysis of population-based data on the use of intermittent strategies [22] in the 'real world' concludes that the use of complete chemotherapy breaks as an intermittent strategy is associated with lower toxicity, without any evidence of negative impact on survival. This study suggests that clinicians are making correct decisions, in concert with their patients, regarding the use of chemotherapy breaks.
Is OS the optimal end point for trials of intermittent delivery of chemotherapy? Allegra et al. have proposed another end point-time-to-failure of strategy (TFS) [23] . They proposed that this end point might preclude the confounding effect of post first-line therapies on OS, and require less extended followup. Indeed, some trials have measured this end point or a variation of it (e.g. DDC in the OPTIMOX studies, PFS2 in CAIRO3 and 'strategy failure-free survival' in the COIN study). One issue with the end points used in the different trials is, as Allegra et al. concede that they all have slightly different definitions. Although there could be value in pooling the information on a failure of strategy end point from different trials, differences in definition between trials would preclude such pooling. As Allegra points out, OS remains an end point that is 'critically important to the patient' and one which allows pooling of data between multiple trials [23] .
Improving patients QoL is of the key goals of intermittent chemotherapy strategies, so it is unfortunate that only three of the trials reported on this important end point. The largest of these trials (COIN) did demonstrate QoL benefits in the intermittent arm at 24 weeks, while the other two trials did not find any QoL differences between arms. However, there were some differences in the assessment of QoL in the trials. The CAIRO 3 trial had the highest compliance rate for completing QoL assessments (88%) but since the data have only been presented in abstract form, there are few details available including the instruments used or the timing of QoL assessments. The timing of the other two trials assessments of QoL was appropriate, but both of those trials had lower compliance rates with their QoL assessments that might have affected their results. Less than two thirds of the patients in the COIN trial completed the QoL assessments. However, the authors did not identify clear differences in baseline characteristics between the general trial population and those who completed QoL questionnaires. In the Maughan et al. study, by the 30-week mark, <30% of patients who started filling out QoL forms were still completing the forms. Details were not provided on the characteristics of the patients who dropped out of QoL assessment in that study, and this may have affected the validity of their findings. Given the importance of QoL in the assessment of intermittent strategies, future studies will need to ensure that they measure this end point, use appropriate instruments at appropriate time points and use strategies to optimize completion of the assessments.
Given that the trials included in this systematic review included a variety of maintenance strategies, including no maintenance treatment, a definitive recommendation regarding an optimal maintenance strategy is not possible. Based on the results of our analysis, clinicians have a range of acceptable strategies they could consider and offer patients who want to consider breaks from continuous full-dose treatment. Strategies that did not use any maintenance therapies may be preferred by patients as it offers them a complete break from treatment. Our analyses of these strategies did not demonstrate any clinically significant detriments in OS. Adaptation of strategies used in these trials may need to be adapted to individual circumstances (for instance, a longer induction period or closer clinical monitoring of patients on maintenance therapy if they have very bulky or symptomatic disease), and some patients may not be appropriate for an intermittent strategy. Six of the eight trials that contributed to the meta-analyses were based on treatments with FOLFOX chemotherapy, while the other two trials included in the meta-analyses used fluoropyrimidine monotherapy or FOLFIRI as induction chemotherapy regimens. Given the acceptability of fluoropyrimidine monotherapy as one of the options for first-line therapy [24, 25, 26] and the accepted equivalence of FOLFIRI and FOLFOX as first-line therapies [27, 28] extrapolation of our conclusions to all commonly used induction chemotherapy regimens is reasonable.
Our analysis does have some limitations. OS HRs were only available for eight of the eleven trials identified. Our meta-analysis is not based on individual patient data. Therefore, differences in individual baseline characteristics cannot be adjusted for. Only two of the eight trials in our analysis included the current standard for first-line treatment of mCRC, combination chemotherapy and a biologic. However the results of both of these two individual trials were consistent with our overall findings. Despite these limitations, the findings of our analysis regarding OS were robust across a series of sensitivity analyses assessing the impact of the various induction and maintenance regimens.
In conclusion, this meta-analysis demonstrates that intermittent strategies of administering first-line systemic therapies to patients with unresectable, mCRC do not result in a statistically significant reduction in OS, and either improve or maintain QoL compared with continuous administration of therapy. Intermittent strategies of administering first-line therapy are a reasonable alternative to continuous administration and should be part of an informed discussion of treatment options for this group of patients.
acknowledgements
The PEBC is supported by the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from the Ministry.
funding
This work is supported by the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from its funding source. No grant numbers apply. disclosure SB has received $5000 or less in a single year to act in a consulting capacity (advisory boards, speaking honoraria) for Sanofi and Roche. TA has received $5000 or more in a single year to act in a consulting capacity for Sanofi Aventis, Roche, and Pfizer. All remaining authors have declared no conflicts of interest. 
